Tags

Type your tag names separated by a space and hit enter

Coffee intake and breast cancer risk in the NIH-AARP diet and health study cohort.
Int J Cancer 2012; 131(2):452-60IJ

Abstract

There are several biologic mechanisms whereby coffee might reduce breast cancer risk. Caffeine and caffeic acid, major coffee constituents, have been shown to suppress mammary tumor formation in animal models and to inhibit DNA methylation in human breast cancer cells, respectively. Coffee may also reduce risk through decreasing inflammation and influencing estrogen metabolism. However, epidemiologic studies have been inconsistent and few studies have examined the association by estrogen and progesterone receptor (ER/PR) status. We evaluated coffee intake for its effect on incident breast cancer in the National Institutes of Health-AARP Diet and Health Study cohort, which included 198,404 women aged 50-71 with no history of cancer, who in 1995-1996 completed a questionnaire capturing usual coffee intake over the past year. State cancer registry and mortality index linkage identified 9,915 primary incident breast carcinomas through December 2006; available information on hormone receptor (HR) status identified 2,051 ER+/PR+ and 453 ER-/PR- cancers. In multivariable proportional hazards models, coffee intake was not associated with breast cancer risk (p-value for trend = 0.38; relative risk = 0.98, 95% confidence interval: 0.91-1.07, for four or more cups per day as compared to women who never drank coffee), and results did not vary by body mass index or history of benign breast biopsy (p-value for interaction > 0.10). We found no evidence of a relationship with either caffeinated or decaffeinated coffee. Null findings persisted for risk of both HR-positive and -negative breast cancers. These findings from a large prospective cohort do not support a role of coffee intake in breast carcinogenesis.

Authors+Show Affiliations

Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, Suite 550, Rockville, MD, USA. gierachg@mail.nih.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Intramural

Language

eng

PubMed ID

22020403

Citation

Gierach, Gretchen L., et al. "Coffee Intake and Breast Cancer Risk in the NIH-AARP Diet and Health Study Cohort." International Journal of Cancer, vol. 131, no. 2, 2012, pp. 452-60.
Gierach GL, Freedman ND, Andaya A, et al. Coffee intake and breast cancer risk in the NIH-AARP diet and health study cohort. Int J Cancer. 2012;131(2):452-60.
Gierach, G. L., Freedman, N. D., Andaya, A., Hollenbeck, A. R., Park, Y., Schatzkin, A., & Brinton, L. A. (2012). Coffee intake and breast cancer risk in the NIH-AARP diet and health study cohort. International Journal of Cancer, 131(2), pp. 452-60. doi:10.1002/ijc.26372.
Gierach GL, et al. Coffee Intake and Breast Cancer Risk in the NIH-AARP Diet and Health Study Cohort. Int J Cancer. 2012 Jul 15;131(2):452-60. PubMed PMID: 22020403.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coffee intake and breast cancer risk in the NIH-AARP diet and health study cohort. AU - Gierach,Gretchen L, AU - Freedman,Neal D, AU - Andaya,Abegail, AU - Hollenbeck,Albert R, AU - Park,Yikyung, AU - Schatzkin,Arthur, AU - Brinton,Louise A, Y1 - 2011/10/20/ PY - 2011/03/05/received PY - 2011/08/02/accepted PY - 2011/10/25/entrez PY - 2011/10/25/pubmed PY - 2012/7/31/medline SP - 452 EP - 60 JF - International journal of cancer JO - Int. J. Cancer VL - 131 IS - 2 N2 - There are several biologic mechanisms whereby coffee might reduce breast cancer risk. Caffeine and caffeic acid, major coffee constituents, have been shown to suppress mammary tumor formation in animal models and to inhibit DNA methylation in human breast cancer cells, respectively. Coffee may also reduce risk through decreasing inflammation and influencing estrogen metabolism. However, epidemiologic studies have been inconsistent and few studies have examined the association by estrogen and progesterone receptor (ER/PR) status. We evaluated coffee intake for its effect on incident breast cancer in the National Institutes of Health-AARP Diet and Health Study cohort, which included 198,404 women aged 50-71 with no history of cancer, who in 1995-1996 completed a questionnaire capturing usual coffee intake over the past year. State cancer registry and mortality index linkage identified 9,915 primary incident breast carcinomas through December 2006; available information on hormone receptor (HR) status identified 2,051 ER+/PR+ and 453 ER-/PR- cancers. In multivariable proportional hazards models, coffee intake was not associated with breast cancer risk (p-value for trend = 0.38; relative risk = 0.98, 95% confidence interval: 0.91-1.07, for four or more cups per day as compared to women who never drank coffee), and results did not vary by body mass index or history of benign breast biopsy (p-value for interaction > 0.10). We found no evidence of a relationship with either caffeinated or decaffeinated coffee. Null findings persisted for risk of both HR-positive and -negative breast cancers. These findings from a large prospective cohort do not support a role of coffee intake in breast carcinogenesis. SN - 1097-0215 UR - https://www.unboundmedicine.com/medline/citation/22020403/Coffee_intake_and_breast_cancer_risk_in_the_NIH_AARP_diet_and_health_study_cohort_ L2 - https://doi.org/10.1002/ijc.26372 DB - PRIME DP - Unbound Medicine ER -